Nordicus Partners CORP 10-K annual reports

Nordicus Partners Corporation files its annual report for the fiscal year ended March 31, 2026, detailing its preclinical biotech developments, acquisitions, and financial performance.

Nordicus Partners Corporation, a U.S. business accelerator for Nordic life sciences companies, reported substantial expansion of its preclinical biotechnology portfolio through key acquisitions and promising drug development milestones, alongside a significant increase in operating expenses and net losses for the fiscal year ended March 31, 2025.

Nordicus Partners Corporation reported its first revenue and made strategic acquisitions in the fiscal year ending March 31, 2024, while also addressing going concern issues.